# Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

> **NCT00706992** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** ALVAC-MART-1 vaccine
- **BIOLOGICAL:** MART-1:26-35(27L) peptide vaccine
- **BIOLOGICAL:** Aldesleukin
- **BIOLOGICAL:** autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
- **BIOLOGICAL:** incomplete Freund's adjuvant

## Key facts

- **NCT ID:** NCT00706992
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** \<11 subjects were enrolled to each Arm
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00706992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00706992, "Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00706992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*